Biophytis Enters Asia Market with Strategic Partnerships

Paris, France, Cambridge (Massachusetts, USA), 22 July 2024 – Biophytis SA, a clinical-stage biotechnology company, has embarked on a new partnership strategy in Asia. The company signed two contracts with local agents to boost its presence in Japan, South Korea, China, and Southeast Asia.

This step is part of Biophytis' broader strategy to speed up the deployment of its drug candidate BIO101 (20-hydroxyecdysone) in this significant market, which is the second-largest pharmaceutical market globally. The agents will utilize their networks to help identify partners for BIO101 in these regions.

Japan and China present key markets for Biophytis. Japan has a substantial population affected by sarcopenia, while China battles a high rate of obesity. These partnerships aim to meet patient needs and facilitate progress in targeted pathologies.

Since signing a licensing agreement with Blanver in Latin America, Biophytis continues to seek co-development and commercialization agreements in Asia and North America, expanding its global footprint.